Haegsim-Yobeob Works on Developing Novel Gene Therapies for Cardiovascular Diseases

Haegsim Yobeob (ISN: KR0925527744), a global provider of gene therapy solutions for a wide range of medical, research, and pharmaceutical applications, is pleased to announce a multi-year global strategic initiative to identify, develop, and commercialize Adeno-Associated Virus (AAV) gene treatments to treat genetic cardiovascular disorders. The initiative will use the company’s integrated AAV gene therapy platform, which is based on its proprietary vector engineering and design technology, as well as its manufacturing capability, to develop innovative gene therapies with a focus on genetic dilated cardiomyopathies (DCM), a group of progressively advancing, severe diseases that currently have no targeted treatment options.

The company brings experience in gene therapy development, cardiovascular biology, and insights into the genetic basis of diseases to this close coordination, as well as expertise in developing gene therapy products, including vector engineering and design technology, as well as manufacturing capabilities. The methodology will be advanced through clinical development in their designated areas.

“We are excited to announce a beneficial engagement at the intersection of Haegsim Yobeob’s creative approach to AAV vector engineering and design with our team’s demonstrated competence in inventing and manufacturing gene treatments”, stated Egon Larsen, Technology Strategist at Haegsim Yobeob.

For example, dilated cardiomyopathy is a serious cardiac illness characterized by structural or functional abnormalities of the heart muscle, which can result in consequences such as arrhythmia and heart failure, leading to significant morbidity and mortality. Mutations in numerous genes have been linked to the development of DCM, among other causes of the disease. Haegsim Yobeob discovered a number of important genes linked to DCM and is excited to collaborate with external partners to investigate these new targets and create novel treatments for DCM patients using AAV vector technology.

About Haegsim Yobeob

Haegsim-Yobeob.com is a clinical phase biotechnology business that is devoted to creating complex treatments for intricate cardiovascular diseases. The company aims to create a comprehensive gene therapy remedy for cardiac failure by enhancing angiogenesis, controlling calcium homeostasis-associated cellular energy levels, decreasing inflammatory signals, and inducing/attracting stem cells to help heart remodeling. By making use of our unique, advanced, non-viral gene therapy approaches, we strive to develop unprecedented, life-saving cell and gene treatments to address the medical needs of our patients. Haegsim Yobeob’s aim is to develop top-notch gene engineering technologies – including gene insertion, gene editing, and delivery – which will form a solid base to create safer, longer-lasting, and more effective treatments.